Abstract
The efficacy of current treatment protocols for childhood cancer is mainly based on empirical studies by adding drugs, changing drug dosages and changing drug combinations. In pediatric acute lymphoblastic leukemia (ALL), this approach has resulted into ∼80% 5-year disease-free survival whereas less favorable results have yet been obtained for acute myeloid leukemia (AML), i.e. ∼50%, and other types of tumors, e.g. ∼60% for medulloblastoma. A further optimization of therapy results requires more insights into the molecular biology of tumor cells, including genetic defects and aberrant expression of genes. This knowledge is needed to rationally develop more specific therapies in which relapse-risk and side-effects of therapy are reduced using targeted drugs. Genome-wide analysis of gene expression levels (mRNA) has revealed many new insights into the biology of leukemic cells. In this review we will discuss the recent progress that has been made in the use of microarrays for identifying new markers and targets for treatment of acute leukemia in children.
Keywords: Gene expression profiling, microarray, classification, drug resistance, outcome, targeted therapy, childhood, acute leukemia
Current Drug Targets
Title: Microarray-Based Identification of New Targets for Specific Therapies in Pediatric Leukemia
Volume: 8 Issue: 6
Author(s): Monique L. den Boer and Rob Pieters
Affiliation:
Keywords: Gene expression profiling, microarray, classification, drug resistance, outcome, targeted therapy, childhood, acute leukemia
Abstract: The efficacy of current treatment protocols for childhood cancer is mainly based on empirical studies by adding drugs, changing drug dosages and changing drug combinations. In pediatric acute lymphoblastic leukemia (ALL), this approach has resulted into ∼80% 5-year disease-free survival whereas less favorable results have yet been obtained for acute myeloid leukemia (AML), i.e. ∼50%, and other types of tumors, e.g. ∼60% for medulloblastoma. A further optimization of therapy results requires more insights into the molecular biology of tumor cells, including genetic defects and aberrant expression of genes. This knowledge is needed to rationally develop more specific therapies in which relapse-risk and side-effects of therapy are reduced using targeted drugs. Genome-wide analysis of gene expression levels (mRNA) has revealed many new insights into the biology of leukemic cells. In this review we will discuss the recent progress that has been made in the use of microarrays for identifying new markers and targets for treatment of acute leukemia in children.
Export Options
About this article
Cite this article as:
den Boer L. Monique and Pieters Rob, Microarray-Based Identification of New Targets for Specific Therapies in Pediatric Leukemia, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830755
DOI https://dx.doi.org/10.2174/138945007780830755 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Ex Vivo Gene Therapy and Vision
Current Gene Therapy Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design Is There a Clinical Future for Spermatogonial Stem Cells?
Current Stem Cell Research & Therapy NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Hemangiomas, Angiosarcomas, and Vascular Malformations Represent the Signaling Abnormalities of Pathogenic Angiogenesis
Current Molecular Medicine Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Pediatric Oral Lichen Planus: Review and Case Report
Current Pediatric Reviews Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry Melatonin a Promising Candidate for DNA Double-Stranded Breaks Reduction in Patients Undergoing Abdomen-Pelvis Computed Tomography Examinations
Anti-Cancer Agents in Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Potential Prophylactic and Therapeutic Vaccines for HSV Infections
Current Pharmaceutical Design